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sponse options; 4) ease of completing the questionnaire; 5) relevancy of the items;
6) formatting (e.g., design and placement of instructions, font, placement of items
on page); and 7) identification of new concepts (e.g., functional areas or activities
that patients consider relevant and not represented by existing items). RESULTS:
Twenty COPD patients were interviewed: 12 (60%) males; mean age  63.0  11.3
years; 14 (70%) Caucasian; 12 (60%) retired; mean FEV1  1.5  0.5 liter; FEV1%
predicted  48.4  13.1. Content of the FPI-SF was seen as comprehensive and
represented activities participants found important and often difficult to perform.
Participants understood the instructions, items, and response options as intended.
No new concepts were identified. Two minor formatting changes were suggested to
improve clarity. CONCLUSIONS: These results, together with its development his-
tory and previously tested quantitative properties, suggest the FPI-SF is content
valid for use in clinical studies of COPD.
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OBJECTIVES: Over the past few decades the treatment of asthma bronchiale has
experienced huge progress. Hospitalizations and emergency visits almost disap-
peared and majority of patients with severe asthma are active in work and leisure
activities. However asthma still presents significant burden on patient’s daily liv-
ing. Objective of the study was to explore the burden of asthma on everyday life
from the patient’s perspective. METHODS: From May till September 2010, 506 pa-
tients were enrolled in a prospective 6 months study in the Slovak Republic with
moderate and severe persistent asthma. A total of 461 patients returned valid
diaries recording everyday asthma related symptoms and use of treatment over
period of 3 months. Clinical and treatment data have been recorded by the physi-
cian for the period of 6 months. RESULTS: The mean age of patients is 50 yrs with
disease duration of 12 years. Majority of patients are women (71%) and with mod-
erate asthma (88%). Most patients are active at work or study (85%) with 11% dis-
abled and only 4% unemployed. 31% patients have ever experienced a negative
impact of asthma on their employment opportunities. The impact of asthma on
everyday life is still large. According to patient diaries the patients suffer from
asthma symptoms (% of days with symptom of all severities/severe symptoms):
any of the monitored symptoms (67/19), dyspnoe (46/8), cough (49/10), wheezing
(32/6), limitation of daily activities (37/8), sleep disturbance (30/9), limitation of
work activities (25/2.5). The need for medical services such as unscheduled visits
(0.53/person year) or hospitalizations (0.036/person year) is less frequent.
CONCLUSIONS: The data demonstrate that asthma is still present in most of pa-
tient days including the presence of symptoms and impact on personal and work
life of patients. Patient insight is very valuable and should be incorporated more
within the routine treatment in order to get asthma under better control.
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OBJECTIVES: This study was designed to evaluate treatment outcome of pulmo-
nary tuberculosis patients by using WHO/IUATLD classification and investigate
factors associated with unsuccessful outcome.METHODS: The study was designed
as a retrospective evaluation of patients with smear confirmed pulmonary tuber-
culosis visiting two specialized hospitals in North East Libya. All patients who
registered during 2008-2009 were enrolled. Standardized protocol was used to col-
lect the required data. Descriptive analysis was computed for demographic and
clinical characteristics. Chi-square test with significance level of 0.05 was used to
determine association between variables. Data was analyzed by Statistical Package
for the Social Sciences version 16.02. RESULTS: Three hundred and twenty seven
patients were notified during the study period. Using the WHO/IUATLD criteria,
cure and treatment completion rate was 1.2% and 57.5%, respectively. Treatment
failure occurred in 7(2.1%) cases. Ninety (27.5%) patients defaulted treatment, 11
(3.4%) died and 26 (8%) transferred out. Nationality, sex, educational level, area of
residence and smoking were associated with unsuccessful treatment outcome.
CONCLUSIONS: Improving clinical and laboratory infrastructure in peripheral ar-
eas, educating defaulters about benefits of completing therapy and stratifying for-
eigners as high risk groups could improve success rate. Measures should be taken
to improve professional commitment and expertise of health care professionals.
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OBJECTIVES: To assess the quality of life (QoL) in patients with severe persistent
uncontrolled asthma and their caregivers, in the asthmatic Spanish pediatric pop-
ulation in specialist consultation. METHODS: An observational, cross-sectional,
multicenter (pneumology and allergy) study was done. Inclusion criteria were:
male and female patients, 6 years old 14, diagnosed with severe persistent
asthma [controlled and uncontrolled (ratio 5:2), according to physician criteria],
with data of clinical history and spirometry in the last 6 months. QoL in pediatric
patients and caregivers using PAQLQ and PACQLQ questionnaires, respectively,
and diagnostic concordance between physician criteria and GEMA, were
determined. RESULTS: A total of 207 patients were included, 33.8% with severe
persistent uncontrolled asthma and mean age SD of 10.4 2.3 vs. 11.5 2.1 years
in patients controlled (p  0.0015). Of all patients, 61.4% were male, BMI were 19.4
 3.8 kg/m2 and time from diagnosis was 5.5 3.4 years. Uncontrolled patients had
a higher number of exacerbations (7.4  5.2 vs. 3.2  2.8, p 0.0001), emergency
room visits number (2.4  3.3 vs 1.0  1.3, p 0.0001), FVC and FEV1 percentage
80% (28.4% vs 18.5%, p 0.0270 and 47.5% vs 28.6%, p 0.0069, respectively). QoL
in uncontrolled patients (114.2  30.2 vs 137.8  25.6) and their caregivers (64.2 
17.3 vs 74.7  17.9) was worse compared to controlled patients (p 0.0001, both).
Concordance between physician versus GEMA asthma control evaluation was
moderate, showing that 34.3% of patients with poor controlled asthma according to
GEMA would be considered controlled according physician criteria (k: 0.4, 95% CI:
0.3-0.6). CONCLUSIONS: Uncontrolled asthma patients have worse QoL, affecting
their caregivers. One third of physicians underestimate patients with uncontrolled
asthma.
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OBJECTIVES: Asthma symptoms can lead to physical and social activities limita-
tions, deteriorating the quality of life (QoL) of patients. Given the high percentage of
asthmatic uncontrolled patients, it is important to assess how the lack of control
affects the QoL. METHODS: An observational, cross-sectional and multicenter
study with severe persistent asthma patients according to GEMA, in specialist
consultation (pneumology and allergy) was done. QoL was assessed using Mini-
AQLQ questionnaire (domains: daily activity limitation, symptoms, emotions and
environment) according to GEMA and physician criteria, and patients’ perception.
Anxiety and depression according to GEMA criteria and patient’s perception, and
hyperventilation were assessed using the Hospital Anxiety and Depression scale
and the Nijmegen questionnaire, respectively. RESULTS: A total of 343 patients
were enrolled, being the mostly women (67.6%). Uncontrolled patients had worse
QoL scores according to GEMA, physician criteria and patient perception [4.4 (1.3)
versus 6.1 (1.0), 4.2 (1.2) versus 5.7 (1.2), 3.9 (1.1) versus 5.5 (1.2), respectively,
p0.0001 in all cases]. These patterns were also observed in the different dimen-
sions of QoL assessed (p0.0001 in all cases). The anxiety was associated with a
poor control asthma according to the GEMA [7.7 (4.4) versus 4.9 (3.1), p0.0003] and
patient perception [8.4 (4.4) versus 6.1 (3.9), p0.0001]. Depression also showed
significant association with poor control according to GEMA and patient perception
[4 (4.3) versus 2.3 (2.7) and 6.2 (4.1) versus 3.5 (3.9), respectively, p0.0001 in both
cases]. Similarly, the degree of hyperventilation was higher in uncontrolled pa-
tients according to GEMA and patients perception [19.2 (10.0) versus 9.6 (8.5) and
21.9 (9.3) versus 13.5 (9.5), respectively, p0.0001 in both cases]. CONCLUSIONS:
Uncontrolled asthma patients have worse quality of life, showing a greater degree
of anxiety, depression and hyperventilation.
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OBJECTIVES: To evaluate the impact of age on health related quality of life in
patients hospitalized for COPD exacerbations, given the fact that little is known on
this aspect. METHODS: Analysis of data from patients with COPD exacerbation
admitted in an university hospital between March and November 2008. Elderly
patients were defined as having an age of at least 65 years. Lung function, dyspnea
level at hospital admission, and health-related quality of life (CCQ, WHO-Five Well
-being Index-WHO-5) were among the variables analyzed comparatively in elderly
(E) and younger (Y) patients respectively. RESULTS: Included in the analysis were
72 patients, 42 (58.3%) were ex smokers, and there were 45 E patients and 27 Y
patients. Elderly patients had more severe dyspnea at admission, more impaired
lung function during hospitalization, and required longer hospitalizations. E pa-
tients had a more impaired health-related quality of life at admission as compared
to Y patients but this was not significantly altered (at admission WHO-5 score 19.28
E versus 22.81 Y, p0.49; CCQ symptoms score 3.64 for E and 3.26 for Y, p0.23; CCQ
functional score 3.63 for E and 3.25 for Y, p0.27, CCQ mental score 3.75 for E and
3.40 for Y, p0.4, CCQ total score 3.66 for E and 3.30 for Y, p0.19). Health-related
quality of life at discharge was found to be slightly and non significantly impaired
in E patients as compared to Y patients. CONCLUSIONS: This analysis demon-
strated that elderly patients hospitalised for a COPD exacerbation had a more
impaired health-related quality of life even if no statistically significant differences
were detected.
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OBJECTIVES: Chronic obstructive pulmonary disease (COPD) has a great impact on
patient’s health-related quality of life (HRQoL). The aims of this study were: 1) to
assess the generic and disease specific HRQoL of COPD patients, and 2) to evaluate
the influence of age and lung function on the patient’s HRQoL. METHODS: In this
observational, cross-sectional study the following information was obtained: age,
lung function (post-bronchodilator forced expiratory volume in one second [FEV1])
and HRQoL (generic: EuroQol five-dimension questionnaire [EQ-5D], disease spe-
cific: St. George’s Respiratory Questionnaire [SGRQ]). Multiple linear regression
model was applied to analyze the effect of age and FEV1 on the HRQoL. RESULTS:
Data collected from 170 patients (mean age 63.8 years, 41.8% male) were analyzed.
The mean EQ-5D score was 0,55 (SD0,21) and the mean SGRQ total score was
56,22% (SD16,19). The multiple linear regression model was successfully applied
to describe the effect of age and FEV1 on the patient’s HRQoL measured by either
EQ-5D (R20,47) or SGRQ (R20,64). Both generic and disease-specific HRQoL were
related with age and lung function (p0.005). CONCLUSIONS: SGRQ and EQ-5D
appear to be reliable and valid for the assessment of HRQoL in COPD patients and
may be used as a non-invasive patient-centered monitoring system as a guide for
the management of COPD. Due to the simplicity of EQ-5D, the use of this instru-
ment can be recommended within routine clinical practice.
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OBJECTIVES:We aimed to explore patients’ perceived positive and negative factors
associated with the use of pharmacological-behavioral combination therapy to
smoking cessation. METHODS: Each patient who visited a drug dependent treat-
ment center was assessed using structured clinical interviews and the Fagerström
Test for Nicotine Dependence (FTND). In-depth interviews were conducted with
patients who agreed to participate in the study. These patients were treated with
behavioral therapy combined with bupropion or nicotine gum and followed up for
three consecutive months. The interview responses were recorded, transcribed
and organized thematically based on emerging codes using an inductive analysis.
RESULTS: Seventeen key informants participated in this study and the mean age
was 38.2 years. Their FTND score varied from 3.0-5.0 and the number of cigarettes
smoked was 3-40 per day. Among these patients 11.8% were able to quit smoking
within 1 month, 29.4% within 2 months, 29.4% within 3 months, and 29.4% could
not quit smoking in any period of the study. Supportive factors to smoking cessa-
tion included supports from family and colleagues, poorer health, role model for
acquaintances, household cost saving, practical advice from encouraging physi-
cians, fear of social blame, smoking-free policy at workplace, and the patients’
proactive strategies to avoid smoking temptation. Nevertheless, some barriers to
smoking cessation were lacking in initiative and readiness to quit smoking; lacking
of family support; incompliance to pharmacological-behavioral therapy; gaining
weight; triggers such as nicotine withdrawal symptoms, stress, being in a party
with smokers; using tobacco as a substitute of other substance; and inconvenient
service time and facility at the treatment center. CONCLUSIONS: This study pro-
vides a framework of interrelated social factors associated with the use of pharma-
cological-behavioral combination therapy to smoking cessation. There is a need for
developing tobacco dependence treatment programs and enabling factors tailored
to meet the needs of patients.
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OBJECTIVES:Most studies assumed defaulters to be similar to smokers in smoking
cessation programmes. Thus, the objective of this qualitative study was to explore
perceptions held by QSC defaulters towards QSC service provision. This study also
examined the smoking and smoking cessation beliefs among the defaulters.
METHODS: Drawing from the patients’ register at two different QSC settings; one
being managed by a team of physicians, medical assistants and nurses while an-
other is managed by the pharmacists, 14 current adult smokers were interviewed
face-to-face, from May 2010 to March 2011. Interviews were audio-recorded and
transcribed verbatim. The data were analyzed using thematic analysis to generate
codes, categories and subsequently themes. RESULTS: This heterogeneous sub-
group of smokers revealed shared ambivalence towards smoking and smoking
cessation, indicating the underlying unreadiness to quit smoking and low self-
efficacy. The dynamic interaction between components of the QSC such as the
degree of relationship established between the health care providers and the effi-
cacy and availability of smoking cessation aids (SCA) were being perceived as ex-
trinsic motivational cues to enable these smokers to quit smoking. Overall these
smokers described the barriers encountered mirrored the unmet expectation; com-
prising of the lack of expected skills and poor attitudes in the health care providers
and the perceived unavailability and ineffective formal smoking cessation aids
provided at the QSC. CONCLUSIONS: It is necessary to optimize the interplay of
extrinsic motivational cues (health care provider and SCA’s factors) in order to
steer these smokers to quit smoking using the QSC approach. This study serves to
underline the need to address a tailored stepped-care approach in these smokers in
relation to gender, socio-economic status and nicotine dependence level, encom-
passing a wider stance in the tobacco control policy.
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OBJECTIVES: The efficacy and safety of omalizumab for the treatment of severe
persistent allergic asthma have been demonstrated in randomised controlled clin-
ical trials. However, there are limited ‘real world’ data on its effects on healthcare
resource utilisation or health-related quality of life (QoL) in UK clinical practice.
METHODS: A 10 centre retrospective observational study (APEX) compared 12
months pre- versus 12 months post-omalizumab initiation in patients aged 12
years with severe persistent allergic asthma. All patients received 1 dose of
omalizumab. Hospital records were reviewed to obtain data on hospital resource
use and routinely used QoL measures e.g. Asthma Quality of Life Questionnaire
(AQLQ ) at baseline (pre-omalizumab), 16 weeks and up to 12 months following
omalizumab initiation. RESULTS: Mean Accident and Emergency department at-
tendances fell by 70% from 1.52 per patient in the 12 months pre-omalizumab to
0.46 in the 12 months post-omalizumab (p0.001). Similarly, mean in-patient hos-
pital admissions fell by 61% from 1.30 to 0.51 (p0.001) and mean in-patient bed
days fell by 70% from 9.10 to 2.74 (p0.001) per patient. In the subgroup of patients
hospitalised for asthma in the 12-months pre-omalizumab (n81), mean in-pa-
tient hospital admissions fell by 70% from 2.19 to 0.65 (p0.001) and mean in-
patient bed days fell by 74% from 14.86 to 3.83 (p0.001) per patient. Other resource
use, such as outpatient attendances (excluding visits made solely for omalizumab
administration), nurse appointments and telephone consultations remained un-
changed following omalizumab initiation. QoL data were not available for all pa-
tients at every time point. However, where data were available, mean AQLQ scores
increased from 3.09 at baseline to 5.01 at 16 weeks (n90) and to 5.22 at 12 months
(n29). CONCLUSIONS: Treatment with omalizumab is associated with a signifi-
cant reduction in unplanned hospital resource utilisation and significant improve-
ments in patients’ QoL.
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OBJECTIVES:Drug use review for the treatment of asthma and assess the impact of
the administrative program to optimize the use of drugs in the Samara region in
2008-2010. METHODS: In 2008 retrospective analysis of drug use in ambulatory
practice based on a database of 90,196 paid prescriptions patients with bronchial
asthma in the Samara region. An analysis of 155 history of 15 clinics. Data on the
consumption of drugs were presented with the ATC/DDD methodology in the form
of DDD/1000 inhabitants day. After the analysis has developed a program that
includes training, administrative controls over the discharge of drugs, medica-
tions, and form a formal application form. In 2009, the evaluation of the implemen-
tation of the optimization program by re-examining the consumption of drugs (105
318 prescriptions paid for) and analysis of hospital records (143 history) RESULTS:
Use of basic products in 2008 amounted to 380, including inhaled corticosteroids
(ICS) was 286, medications to relieve symptoms - 485 DDD 1000 inhabitants/day. In
2009, use of basic drugs increased by 1.6 times to 621, the consumption of inhaled
corticosteroids has increased by 1.7 times to 502 DDD per 1000 inhabitants/day, (p
0.001). In 2009 compared to 2008 the number of patients with nocturnal symp-
toms dropped from 52% to 37%; of hospitalization from 47% to 25%; ambulance call
from 40% to 23%, respectively (p 0.001). CONCLUSIONS: The introduction of a
rational program for the use of drugs with the use of administrative controls in 2009
allowed the drug to optimize the consumption of patients with asthma to improve
asthma control in clinical practice and to reduce the costs of the use of medical
resources.
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OBJECTIVES: This study analyses consumption patterns of fluoroquinolones and
documents in vitro resistance of S. pneumoniae to fluoroquinolones in ambulatory
care in Belgium. METHODS: Data on fluoroquinolone consumption were derived
from IMS Health. Volume of consumption was expressed in terms of the number of
defined daily doses per 1,000 inhabitants per day (DID). Consumption was valued at
public prices pertaining to the year or month of consumption. Respiratory blood
isolates were taken from adults to test in vitro susceptibility of S. pneumoniae to
levofloxacin and moxifloxacin. The S. pneumoniae strains were isolated in 15 clinical
laboratories throughout Belgium. A hundred blood isolates per year were at ran-
dom selected from 2004 to 2009. Susceptibility and resistance of S. pneumoniae was
expressed using the Clinical and Laboratory Standards Institute breakpoints.
RESULTS: Fluoroquinolone consumption increased from 24.1 million € in 1993 to a
maximum of 44.4 million € in 2002, and then decreased to 35.0 million € in 2009. The
volume of fluoroquinolone consumption has fallen consistently from 3.00 DIDs in
2003 to 2.66 DIDs in 2009. Fluoroquinolones were primarily used to treat urinary
tract infections (36% of consumption, volume of 0.95 DIDs) and lower respiratory
tract infections (26% of consumption, volume of 0.70 DIDs). The minimum inhibi-
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